The Recover Kit produces autologous platelet-rich plasma to treat chronic tendon elbow. The study was a multicenter, prospective, randomized, controlled, double-blind clinical trial and will be completed when each of the enrolled 230 patients reaches a 24-week follow-up in mid-2011.
The trial is being performed under FDA-approved investigational device exemption to evaluate the safety of the device. The study subjects will receive investigational PRP treatment or bupivacaine as the control.
Read the Benzinga report on Biomet’s Recover Kit.
Read more coverage on Biomet:
– Biomet Nederland, Small Bone Innovations Sign Distribution Agreement
– Biomet Acquires Massachusetts’ Cytosol Laboratories
– Biomet Announces 4Q FY 2010 Financial Results
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
